ENTA
Enanta Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.08
+0.43%Year over year
Reported trailing growth
- Revenue
- +0.7%
- EBITDA
- +43.6%
- EBIT
- +39.3%
- EPS
- +44.3%
- Free cash flow
- +15.2%
- Operating cash flow
- -52.3%
Forward estimates
Based on analyst estimates
- Revenue
- -5.0%
- EBITDA
- +8.1%
- EPS
- +11.4%
Three-year CAGR
- Revenue
- -8.8%
- EBITDA
- +32.3%
- EBIT
- +29.9%
- Net income
- +29.4%
- EPS
- +29.9%
- Free cash flow
- +66.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026